RPHM / Reneo Pharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

2,938,005 Shares of Class A Common Stock

PROSPECTUS SUPPLEMENT (to Prospectus dated March 21, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 ONKURE THE

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update -- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent a

Exhibit 99.1 OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 - Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestra

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commissi

Legends Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of OnKure Therapeutics, Inc. (“OnKure” or the “Company”). All statements other than statements of historical fac

Corporate Overview June 2025 Exhibit 99.1 Legends Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of OnKure Therapeutics, Inc. (“OnKure” or the “Company”). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commission

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commission

FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. Item 9.01 Financial Statements and Exhibits.

PROSPECTUS SUPPLEMENT (to Prospectus dated March 21, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 ONKURE TH

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commission

2,938,005 Shares of Class A Common Stock

PROSPECTUS SUPPLEMENT (to Prospectus dated March 21, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No.

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combinati

Exhibit 99.1 OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data - Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D

2,938,005 Shares of Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-282792 PROSPECTUS 2,938,005 Shares of Class A Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 2,938,005 shares of Class A Common Stock, par value $0.0001 per shar

As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. 333-282792 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Sec

As filed with the Securities and Exchange Commission on March 20, 2025 Registration No.

Insider Trading Policy

Exhibit 19 ONKURE THERAPEUTICS, INC. INSIDER TRADING POLICY (Adopted on October 4, 2024; Effective upon the closing of the merger contemplated by the Registration Statement on Form S-4 (File No. 333-280369)) A. POLICY OVERVIEW OnKure Therapeutics, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the fed

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights -- PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 20

Exhibit 99.1 OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 - Expansion of PI3Ka franchise to include a pan-mutant selective program; devel

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40315 ONKURE THERAPE

2,938,005 Shares of Class A Common Stock

PROSPECTUS SUPPLEMENT (to Prospectus dated October 30, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.

As filed with the Securities and Exchange Commission on March 10, 2025

As filed with the Securities and Exchange Commission on March 10, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. Compensation Recovery Policy

Exhibit 97 ONKURE THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY (Adopted on August 23, 2024; Effective upon the closing of the merger contemplated by the Registration Statement on Form S-4 (File No. 333-280369)) OnKure Therapeutics, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawbac

Description of Capital Stock of the Registrant.

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description provides a summary only and does not contain all of the information that may be important to you. It is therefore qualified by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, copies of which are filed with the U.S. Securities and Exchange Commission as exhibits to the Annual R

List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 10, 2025).

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Organization Radiate Merger Sub II, LLC Delaware OnKure, Inc. Delaware

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commis

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or disconti

EX-99.1 2 okur-ex991.htm EX-99.1 Exhibit 99.1 OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 - OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported - Initial patient data show exposures of OKI-219 exceeding levels associated with

2,938,005 Shares of Class A Common Stock

PROSPECTUS SUPPLEMENT (to Prospectus dated October 30, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.

Legends Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of OnKure Therapeutics, Inc. (“OnKure” or the “Company”). All statements other than statements of historical fac

Corporate Overview December 2024 Exhibit 99.2 Legends Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of OnKure Therapeutics, Inc. (“OnKure” or the “Company”). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, result

As filed with the Securities and Exchange Commission on December 9, 2024

As filed with the Securities and Exchange Commission on December 9, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OnKure Therapeutics, Inc.

OKUR / OnKure Therapeutics, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 1 Passive Investment

SC 13G/A 1 okur1015243sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* OnKure Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of This Statement) Check

RPHM / Reneo Pharmaceuticals, Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC - ONKURE THERAPEUTICS, INC. Passive Investment

SC 13G 1 p24-3243sc13g.htm ONKURE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement

2,938,005 Shares of Class A Common Stock

PROSPECTUS SUPPLEMENT (to Prospectus dated October 30, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 ONKUR

INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Exhibit 99.1 INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS UNAUDITED CONDENSED FINANCIAL STATEMENTS: Page Independent Auditors' Review Report 2 Unaudited Balance Sheets as of September 30, 2024 and December 31, 2023 3 Unaudited Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 4 Unaudited Statements of Changes in Convertible Preferr

Letter regarding Unaudited Interim Financial Information

Exhibit 15.1 November 7, 2024 OnKure, Inc. Boulder, CO Re: Form 8-K dated November 7, 2024 With respect to the subject current report, we acknowledge our awareness of the use therein of our report dated November 7, 2024 related to our review of interim financial information. Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a registration statem

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K of which this exhibit forms a part, including Exhibit 99.1 and 99.2 thereto, unless defined below. On May 10, 2024, Reneo entered into the Merger Agreement with Merger Sub I, Merger Sub II and Legacy O

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 OnKure Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commis

Letter from Ernst & Young, LLP dated November 7, 2024

Exhibit 16.1 November 7, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated November 7, 2024, of OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) and are in agreement with the statements contained in the second through fourth paragraphs as reported under Item 4.01(a) therein. We have no basis to ag

Three Months Ended

Exhibit 99.2 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations together with our (i) unaudited consolidated interim financial statements as of and for the periods ended September 30, 2024 and 2023 and related notes thereto, filed as Exhibit 99.1 to

2,938,005 Shares of Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-282792 PROSPECTUS 2,938,005 Shares of Class A Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 2,938,005 shares of Class A Common Stock, par value $0.0001 per shar

October 28, 2024

October 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: OnKure Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-282792 Acceleration Request Requested Date:   October 30, 2024 Requested Time:    4:30 p.m. Eastern Time, or as soon thereafter as practicable Ladi

Octagon Capital Advisors LP - AMENDMENT NO. 1

SC 13G/A 1 y1028240sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OnKure Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of This Statement) Chec

Power of Attorney (see the signature page to this Registration Statement on Form S-1)

Table of Contents As filed with the Securities and Exchange Commission on October 23, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OnKure Therapeutics, Inc.

Deep Track Capital, LP

SC 13G/A 1 deeptrack-okur100424a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ONKURE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CUSIP Number) October 22, 2024 (Date of Event Which Requires Filing of this Statement) Ch

Cormorant Asset Management, LP

SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OnKure Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th

Samsara BioCapital, L.P. - SC 13G

SC 13G 1 tm2426046d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OnKure Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statemen

JOINT FILING AGREEMENT

EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 11, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare Fund IV,

Deep Track Capital, LP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Cormorant Asset Management, LP

SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OnKure Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r

CITADEL ADVISORS LLC - SC 13G

SC 13G 1 tm2426074d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* OnKure Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (the “Shar

JOINT FILING AGREEMENT

EX-99.1 2 tm2426074d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of OnKure Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 193

Carlyle Group Inc. - SC 13D/A

SC 13D/A 1 d889611dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* OnKure Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 10, 2024 PERCEPTIVE ADVISORS LLC B

POWER OF ATTORNEY

EX-99.6 2 d889611dex996.htm EX-99.6 Exhibit 6 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederi

PERCEPTIVE ADVISORS LLC - SC 13G

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OnKure Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

RPHM / Reneo Pharmaceuticals, Inc. / BML Investment Partners, L.P. Passive Investment

SC 13G/A 1 bml13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 2 )* OnKure Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CU

ACORN BIOVENTURES, L.P. - SC 13G

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ONKURE THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 68277Q105 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

Joint Filing Agreement

EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each

OnKure, Inc. 2023 RSU Equity Incentive Plan, as amended, and forms of agreement thereunder

Exhibit 10.18 ONKURE, INC. 2023 RSU EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Restricted Stock Units. 2.

2024 Employee Stock Purchase Plan

Exhibit 10.15 ONKURE THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of this Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for this Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under

— OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer — On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 — Post

Exhibit 99.4 Source: Reneo Pharmaceuticals, Inc. October 04, 2024 16:57 ET OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million — OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer — On track to announce early clinical data for its lead

Unaudited Pro Forma Condensed Combined Balance Sheets As of June 30, 2024 (In thousands) Historical OnKure Reneo Transaction Accounting Adjustments Note 4 Pro Forma Combined Total Assets Current assets: Cash and cash equivalents $ 18,633 $ 35,970 $ 5

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included elsewhere in this Current Report on Form 8-K. On May 10, 2024, Reneo entered into the Merger Agreement by and among Reneo Pharmaceuticals, Inc. (“Reneo”), Merger Sub I, Merger Sub II and Legacy OnKure, pursuant to which, on the Closing Dat

OnKure Therapeutics, Inc. Executive Incentive Compensation Plan

Exhibit 10.19 ONKURE THERAPEUTICS, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payabl

OnKure, Inc. 2021 Stock Incentive Plan, as amended, and forms of agreement thereunder

Exhibit 10.17 ONKURE, INC. 2021 STOCK INCENTIVE PLAN (as amended) TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 4 3.1 Board 4 3.2 Committee 4 3.3 Grants 5 3.4 Deferral Arrangement 6 3.5 No Liability 6 4. STOCK SUBJECT TO THE PLAN 6 4.1 Number of Shares Available 6 4.2 Adjustments in Authorized Shares 7 5. GRANT ELIGIBILITY AND LIMITATIONS 7 5.1 Service Provider

Independent Auditors’ Review Report

Exhibit 99.2 Independent Auditors’ Review Report Board of Directors and Stockholders OnKure, Inc.: Results of Review of Interim Financial Information We have reviewed the financial statements of OnKure, Inc. (the Company), which comprise the balance sheet as of June 30, 2024, and the related statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders’ d

OnKure, Inc. 2011 Stock Incentive Plan, as amended, and forms of agreement thereunder

Exhibit 10.16 ONKURE, INC. 2011 STOCK INCENTIVE PLAN (as amended) TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 4 3.1 Board 4 3.2 Committee 4 3.3 Grants 5 3.4 Deferral Arrangement 6 3.5 No Liability 6 4. STOCK SUBJECT TO THE PLAN 6 4.1 Number of Shares Available 6 4.2 Adjustments in Authorized Shares 7 5. GRANT ELIGIBILITY AND LIMITATIONS 7 5.1 Service Provider

Amended and Restated Certificate of Incorporation, as amended.

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENEO PHARMACEUTICALS, INC. Reneo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), hereby certifies that: ONE: The date of filing of the Company’s original certificate of incorporation with the Delaware Secretary of State was September 22, 2014. TWO: The Amended and

Regulation FD Disclosure, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 ONKURE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commissi

OnKure Therapeutics, Inc. Form of Executive Employment Agreement

Exhibit 10.20 ONKURE, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of the Effective Date (as defined below) by and among OnKure, Inc. (the “Company”), Reneo Pharmaceuticals, Inc., (which following the Effective Date (as defined below), will be OnKure Therapeutics, Inc.) (“OnKure”) and [NAME] (“Executive”). Certain capitalized terms used in this Agreement

RPHM / Reneo Pharmaceuticals, Inc. / New Enterprise Associates 15, L.P. - NEW ENTERPRISE ASSOCIATES 15, L.P. / ONKURE THERAPEUTICS, INC. -- SCHEDULE 13D/A(#2E) Activist Investment

SC 13D/A 1 nea15-onkure18889.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / ONKURE THERAPEUTICS, INC. - SCHEDULE 13D/A(#2E) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* OnKure Therapeutics, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 75974E103 (CUSIP Number) Stepha

Amended and Restated Bylaws

Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF ONKURE THERAPEUTICS, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office of OnKure Therapeutics, Inc. (the “corporation”) in the State of Delaware shall be fixed in the corporation’s certificate of incorporation, as the same may be amended from time to time (the “Certificate of Incorporation”). Section 2. Other Offices. The corporat

2024 Equity Incentive Plan and forms of agreement thereunder

Exhibit 10.14 ONKURE THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN 1. Purposes of this Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock O

Report of Independent Registered Public Accounting Firm

Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders OnKure, Inc.: Opinion on the Financial Statements We have audited the accompanying balance sheets of OnKure, Inc. (the Company) as of December 31, 2023 and 2022, the related statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders’ deficit,

OnKure Therapeutics, Inc. Outside Director Compensation Policy

Exhibit 10.21 ONKURE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Reneo Pharmaceuticals, Inc. (which, as of the Closing, as defined in that certain Agreement and Plan of Merger entered into by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC, and OnKure, Inc., dated May 10, 2024, as may be amended from time to time (the “Merger Agreement”) is

Registration Rights Agreement dated October 4, 2024 by and among OnKure Therapeutics, Inc. and certain parties thereto

Exhibit 10.23 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of October 4, 2024, by and among Reneo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several investors signatory hereto (each, an “Investor” and collectively, the “Investors”). RECITALS WHEREAS, the Company is par

Form of Indemnification Agreement

Exhibit 10.22 ONKURE THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [DATE], and is between OnKure Therapeutics, Inc., a Delaware corporation (the “Company”), and [NAME] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of co

Subsidiaries of OnKure Therapeutics, Inc.

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Organization Reneo Pharma Ltd England and Wales OnKure, Inc. Delaware

Certificate of Amendment to Amended and Restated Certificate of Incorporation.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENEO PHARMACEUTICALS, INC. Reneo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is Reneo Pharmaceuticals, Inc. The Company’s original Certificate of Incorporation was filed with the Secreta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 26, 2024 Reneo Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 26, 2024 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 26, 2024 Reneo Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 26, 2024 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Co

JOINT FILING AGREEMENT

EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Reneo Pharmaceuticals, Inc. and further agree to the filin

RPHM / Reneo Pharmaceuticals, Inc. / TANG CAPITAL PARTNERS LP Passive Investment

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Schedule 13G to amend the Schedule 13D filed by Tang Capital Partners, LP and related parties on December 26, 2023 Reneo Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 20, 2024 Reneo Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 20, 2024 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Co

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): September 20, 2024 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Reneo Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Comm

PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280369 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the stockholders of Reneo Pharmaceuticals, Inc. and OnKure, Inc.: On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“Reneo”), entered into an Agreement and Plan of Merger (the “Merger Agreement” and the transactions contemplated thereby, the “Proposed Tr

As filed with the Securities and Exchange Commission on August 26, 2024.

S-4/A Table of Contents As filed with the Securities and Exchange Commission on August 26, 2024.

Consent of Leerink Partners LLC

Exhibit 99.1 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated May 10, 2024, to the Board of Directors of Reneo Pharmaceuticals, Inc., included as Annex L to the proxy statement/prospectus which forms a part of Amendment No. 3 to the Registration Statement on Form S-4 of Reneo Pharmaceuticals, Inc., to be filed on the date hereof, and to the references to suc

Awareness Letter of KPMG LLP for the Quarters ended June 30, 2024 and 2023.

EX-15.1 Exhibit 15.1 August 26, 2024 OnKure, Inc. Boulder, CO Re: Registration Statement No. 333-280369 With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated August 19, 2024 related to our review of interim financial information. Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612 August 23, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Gary Newberry   Lynn Dicker   Tyler Howes   Tim Buchmiller Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-4 (File No. 33

OnKure Therapeutics, Inc. Outside Director Compensation Policy.

Exhibit 10.34 ONKURE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Reneo Pharmaceuticals, Inc. (which, as of the Closing, as defined in that certain Agreement and Plan of Merger entered into by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC, and OnKure, Inc., dated May 10, 2024, as may be amended from time to time (the “Merger Agreement”) is

As filed with the Securities and Exchange Commission on August 19, 2024.

S-4/A Table of Contents As filed with the Securities and Exchange Commission on August 19, 2024.

OnKure Therapeutics, Inc. Form of Executive Employment Agreement.

Exhibit 10.32 ONKURE, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of the Effective Date (as defined below) by and among OnKure, Inc. (the “Company”), Reneo Pharmaceuticals, Inc., (which following the Effective Date (as defined below), will be OnKure Therapeutics, Inc.) (“OnKure”) and [NAME] (“Executive”). Certain capitalized terms used in this Agreement

Awareness Letter of KPMG LLP for the Quarters ended June 30, 2024 and 2023.

Exhibit 15.1 August 19, 2024 OnKure, Inc. Boulder, CO Re: Registration Statement No. 333-280369 With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated August 19, 2024 related to our review of interim financial information. Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a registr

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612 August 19, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention:  Gary Newberry Lynn Dicker Tyler Howes Tim Buchmiller Re: Reneo Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-

OnKure Therapeutics, Inc. Form of Executive Incentive Compensation Plan.

Exhibit 10.31 ONKURE THERAPEUTICS, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payabl

OnKure Therapeutics, Inc. Form of Stock Option Agreement under the 2024 Equity Incentive Plan.

Exhibit 10.33 ONKURE THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, each capitalized term used in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the “Notice of Grant”), the Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, the Exercise Notice, attached hereto a

Consent of Leerink Partners LLC

Exhibit 99.1 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated May 10, 2024, to the Board of Directors of Reneo Pharmaceuticals, Inc., included as Annex L to the proxy statement/prospectus which forms a part of Amendment No. 2 to the Registration Statement on Form S-4 of Reneo Pharmaceuticals, Inc., to be filed on the date hereof, and to the references to suc

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo Phar

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commis

Consulting Agreement, dated May 10, 2024, by and between the Registrant and Michael P. Cruse.

Exhibit 10.4 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) dated as of May 10, 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Michael Cruse (“Consultant”). RECITALS WHEREAS, the Company believes that Consultant’s expertise and knowledge will enhance the Company’s business; and WHEREAS, the Company wishes to retain C

Consulting Agreement, dated May 10, 2024, by and between the Registrant and Gregory J. Flesher.

Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) dated as of May 10, 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gregory J. Flesher (“Consultant”). RECITALS WHEREAS, the Company believes that Consultant’s expertise and knowledge will enhance the Company’s business; and WHEREAS, the Company wishes to ret

Consulting Agreement, dated May 10, 2024, by and between the Registrant and Ashley F. Hall, J.D.

Exhibit 10.5 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) dated as of May 10 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ashley Hall (“Consultant”). RECITALS WHEREAS, the Company believes that Consultant’s expertise and knowledge will enhance the Company’s business; and WHEREAS, the Company wishes to retain Cons

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commis

Consulting Agreement, dated May 10, 2024, by and between the Registrant and Alejandro Dorenbaum, M.D.

Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) dated as of May 10, 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Alejandro Dorenbaum (“Consultant”). RECITALS WHEREAS, the Company believes that Consultant’s expertise and knowledge will enhance the Company’s business; and WHEREAS, the Company wishes to re

As filed with the Securities and Exchange Commission on July 26, 2024.

S-4/A Table of Contents As filed with the Securities and Exchange Commission on July 26, 2024.

Consent of Leerink Partners LLC

Exhibit 99.1 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated May 10, 2024, to the Board of Directors of Reneo Pharmaceuticals, Inc., included as Annex L to the proxy statement/prospectus which forms a part of Amendment No. 1 to the Registration Statement on Form S-4 of Reneo Pharmaceuticals, Inc., to be filed on the date hereof, and to the references to suc

Awareness Letter of KPMG LLP for the Quarters ended March 31, 2024 and 2023.

EX-15.1 Exhibit 15.1 July 26, 2024 OnKure, Inc. Boulder, CO Re: Registration Statement No. 333-280369 With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated June 20, 2024 related to our review of interim financial information. Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a reg

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, CA 92612 July 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Gary Newberry   Lynn Dicker   Tyler Howes   Tim Buchmiller Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-4 Filed June 21,

Consent of Andrew Phillips, Ph.D. to be named as a Director of Reneo, to be renamed OnKure Therapeutics, Inc.

Exhibit 99.5 Consent to be Named as a Director In connection with the filing by Reneo Pharmaceuticals, Inc. (the “Company”) of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Regist

Consent of R. Michael Carruthers to be named as a Director of Reneo, to be renamed OnKure Therapeutics, Inc.

Exhibit 99.4 Consent to be Named as a Director In connection with the filing by Reneo Pharmaceuticals, Inc. (the “Company”) of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Regist

OnKure, Inc. 2011 Stock Incentive Plan, as amended, and forms of agreement thereunder

Exhibit 10.28 ONKURE, INC. 2011 STOCK INCENTIVE PLAN (as amended) TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 4 3.1 Board 4 3.2 Committee 4 3.3 Grants 5 3.4 Deferral Arrangement 6 3.5 No Liability 6 4. STOCK SUBJECT TO THE PLAN 6 4.1 Number of Shares Available 6 4.2 Adjustments in Authorized Shares 7 5. GRANT ELIGIBILITY AND LIMITATIONS 7 5.1 Service Provider

Consent of Isaac Manke, Ph.D. to be named as a Director of Reneo, to be renamed OnKure Therapeutics, Inc.

Exhibit 99.3 Consent to be Named as a Director In connection with the filing by Reneo Pharmaceuticals, Inc. (the “Company”) of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Regist

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-4 (Form Type) RENEO PHARMACEUTICALS, INC.

As filed with the Securities and Exchange Commission on June 20, 2024.

S-4 Table of Contents As filed with the Securities and Exchange Commission on June 20, 2024.

Consent of Nicholas A. Saccomano, Ph.D. to be named as a Director of Reneo, to be renamed OnKure Therapeutics, Inc.

Exhibit 99.2 Consent to be Named as a Director In connection with the filing by Reneo Pharmaceuticals, Inc. (the “Company”) of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Regist

Consent of Leerink Partners LLC.

Exhibit 99.7 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated May 10, 2024, to the Board of Directors of Reneo Pharmaceuticals, Inc., included as Annex L to the proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Reneo Pharmaceuticals, Inc., to be filed on the date hereof, and to the references to such opinion in such p

OnKure, Inc. 2021 Stock Incentive Plan, as amended, and forms of agreement thereunder

Exhibit 10.29 ONKURE, INC. 2021 STOCK INCENTIVE PLAN (as amended) TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 4 3.1 Board 4 3.2 Committee 4 3.3 Grants 5 3.4 Deferral Arrangement 6 3.5 No Liability 6 4. STOCK SUBJECT TO THE PLAN 6 4.1 Number of Shares Available 6 4.2 Adjustments in Authorized Shares 7 5. GRANT ELIGIBILITY AND LIMITATIONS 7 5.1 Service Provider

Consent of Valerie M. Jansen to be named as a Director of Reneo, to be renamed OnKure Therapeutics, Inc.

Exhibit 99.6 Consent to be Named as a Director In connection with the filing by Reneo Pharmaceuticals, Inc. (the “Company”) of the Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Regist

Awareness Letter of KPMG LLP for the Quarters ended March 31, 2024 and 2023.

Exhibit 15.1 June 20, 2024 OnKure, Inc. Boulder, CO Re: Registration Statement No. 333-XXXXX With respect to the subject registration statement, we acknowledge our awareness of the use therein of our report dated June 20, 2024 related to our review of interim financial information. Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a registration

OnKure, Inc. 2023 RSU Equity Incentive Plan, and forms of agreement thereunder

Exhibit 10.30 ONKURE, INC. 2023 RSU EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Restricted Stock Units. 2.

RPHM / Reneo Pharmaceuticals, Inc. / BML Investment Partners, L.P. Passive Investment

SC 13G/A 1 bml13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E103 (

Letter Agreement by and between Reneo Pharmaceuticals, Inc. and Jennifer Lam

Exhibit 10.5 May 10, 2024 Jennifer Lam 1732 La Colina Dr Santa Ana, CA 92705 Re: Retention Bonus and Severance Benefits Dear Jenn, As recognition of your important role at Reneo Pharmaceuticals, Inc. (the “Company”), and to incentivize your continued engagement and employment through 2024, the Company is pleased to offer you a retention bonus described below. Retention Bonus If you remain continuo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): May 10, 2024 Reneo Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): May 10, 2024 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commissi

Form of Reneo Support Agreement (incorporated by reference to Exhibit 10.1 to Reneo’s Current Report on Form 8-K filed on May 13, 2024).

Exhibit 10.1 RENEO PHARMACEUTICALS, INC. PARENT SUPPORT AGREEMENT THIS PARENT SUPPORT AGREEMENT (this “Agreement”), dated as of [•], 2024 is made by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), OnKure, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHEREAS, Parent, Radiat

Subscription Agreement dated May 10, 2024 (incorporated by reference to Exhibit 10.4 to Reneo’s Current Report on Form 8-K filed on May 13, 2024).

Exhibit 10.4 Execution Version SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of May 10, 2024 (the “Effective Date”), by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the individuals and entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”). WHEREAS, the Company is

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

Exhibit 99.1 Reneo Pharmaceuticals and OnKure Announce Proposed Merger Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and run

Form of OnKure Support Agreement (incorporated by reference to Exhibit 10.2 to Reneo’s Current Report on Form 8-K filed on May 13, 2024).

EX-10.2 Exhibit 10.2 ONKURE, INC. COMPANY SUPPORT AGREEMENT THIS COMPANY SUPPORT AGREEMENT (this “Agreement”), dated as of [•], 2024 is made by and among Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), OnKure, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Parent, Radiat

Legends Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied sta

EX-99.2 Exhibit 99.2 Merger Announcement May 2024 WRITING THE NEXT CHAPTER IN PRECISION MEDICINES FOR PATIENTS WITH CANCER Legends Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the struc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): May 10, 2024 Reneo Pharmaceutica

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: (Date of earliest event reported): May 10, 2024 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Comm

Agreement and Plan of Merger, dated May 10, 2024, by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC and OnKure, Inc. (incorporated by reference to Exhibit 2.1 to Reneo’s Current Report on Form 8-K filed on May 13, 2024).

EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among RENEO PHARMACEUTICALS, INC. RADIATE MERGER SUB I, INC. RADIATE MERGER SUB II, LLC and ONKURE, INC. Dated as of May 10, 2024 ARTICLE I DEFINITIONS & INTERPRETATIONS 4 Section 1.1 Certain Definitions 4 Section 1.2 Interpretation 14 Section 1.3 Currency 14 ARTICLE II THE MERGER 15 Section 2.1 Formation of Merger Subs 15 Section 2.2 The Merg

Form of Consulting Agreement (incorporated by reference to Exhibit 10.6 to Reneo’s Current Report on Form 8-K filed on May 13, 2024).

EX-10.6 Exhibit 10.6 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) dated as of [•], 2024, is entered into by and between Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [•] (“Consultant”). RECITALS WHEREAS, the Company believes that Consultant’s expertise and knowledge will enhance the Company’s business; and WHEREAS, the Company wishes to retain Consul

Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.3 to Reneo’s Current Report on Form 8-K filed on May 13, 2024).

EX-10.3 LOCK-UP AGREEMENT [•], 2024 Reneo Pharmaceuticals, Inc. 18575 Jamboree Road Suite 275-S Irvine, CA 92612 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Reneo Pharmaceuticals, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of May 10, 2024 (as the same may be amended fr

RPHM / Reneo Pharmaceuticals, Inc. / New Enterprise Associates 15, L.P. - NEW ENTERPRISE ASSOCIATES 15, L.P. / RENEO PHARMA -- SCHEDULE 13D/A(#1) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 75974E103 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 (410) 842-40

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commission

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 7, 2024 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commiss

Reneo Pharmaceuticals, Inc. Incentive Compensation Repayment Policy.

Exhbit 97.1 Reneo Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Reneo Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on March 28, 2024

As filed with the Securities and Exchange Commission on March 28, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40315 RENEO PHARMACE

Issuer Purchases of Equity Securities.

Exhibit 26.1 ISSUER PURCHASES OF EQUITY SECURITIES Period (a) Total Number of Shares (or Units) Purchased (b) Average Price Paid per Share (or Unit) (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs October 1 – October 31, 2023 57

Subsidiaries of Reneo Pharmaceuticals, Inc. (incorporated by reference to Exhibit 21.1 to Reneo’s Annual Report on Form 10-K filed on March 28, 2024).

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Organization Reneo Pharma Ltd England and Wales

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Comm

RPHM / Reneo Pharmaceuticals, Inc. / Octagon Capital Advisors LP Passive Investment

SC 13G 1 j15240sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RENEO PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 75974E103 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to d

RPHM / Reneo Pharmaceuticals, Inc. / BML Investment Partners, L.P. Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E103 (CUSIP Number) January 10,

RPHM / Reneo Pharmaceuticals, Inc. / TANG CAPITAL PARTNERS LP Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no.

RPHM / Reneo Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A 1 d68745dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E 103 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Reneo Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Comm

Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 (858) 283-0280

Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 (858) 283-0280 November 17, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-275518 Ladies and Gentlemen: Pursuant to Rule 461

Form of Indenture, by and between the Registrant and one or more trustees to be named.

EX-4.3 Exhibit 4.3 RENEO PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif

Up to $100,000,000 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264616 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2022) Up to $100,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying prosp

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results Topline data results from the pivotal STRIDE study are expected in December 2023 IRVINE, Calif., November 13, 2023 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochond

As filed with the Securities and Exchange Commission on November 13, 2023

S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2023 Registration No.

Sales Agreement, dated November 13, 2023, by and between the Registrant and Leerink Partners LLC.

Exhibit 10.1 RENEO PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT November 13, 2023 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.6 Exhibit 4.6 RENEO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF RENEO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RENEO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.8 Exhibit 4.8 RENEO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF RENEO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RENEO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associatio

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.7 Exhibit 4.7 RENEO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF RENEO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RENEO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associatio

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Reneo Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commi

Today’s Speakers Welcome & Opening Remarks Gregory J. Flesher President & CEO Reneo Pharmaceuticals, Inc. Overview of Mitochondrial Disease Amel Karaa, MD Director of the Mito Clinic Massachusetts General Hospital Harvard Medical School Mavodelpar De

EX-99.1 Exhibit 99.1 Focused on Improving the Lives of Patients with Rare Genetic Mitochondrial Diseases K Ke ey y O Opi pin niio on n L Le ead ade er r an and d Man Manag age em me en nt t U Updat pdate e October 9, 2023 Forward-Looking Statements This presentation contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 Reneo Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo Phar

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23 IRVINE, Calif., August 10, 2023 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commis

Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 (858) 283-0280

CORRESP Reneo Pharmaceuticals, Inc. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 (858) 283-0280 June 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-272421 Ladies and Gentlemen: Pursuant to Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commissio

As filed with the Securities and Exchange Commission on June 5, 2023

S-3 Table of Contents As filed with the Securities and Exchange Commission on June 5, 2023 Registration No.

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Reneo Pharmaceuticals, Inc.

RPHM / Reneo Pharmaceuticals Inc / RiverVest Venture Fund III, L.P. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.

RPHM / Reneo Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E 103 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commissio

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

Exhibit 99.1 Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results • Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023 • Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company foc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo Pha

RPHM / Reneo Pharmaceuticals Inc / Carlyle Group Inc. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E103 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-562

Underwriting Agreement, dated as of May 3, 2023, by and among Reneo Pharmaceuticals, Inc. and Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein

Exhibit 1.1 6,875,000 Shares Reneo Pharmaceuticals, Inc. UNDERWRITING AGREEMENT May 3, 2023 JEFFERIES LLC BOFA SECURITIES, INC. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota

Securities Purchase Agreement, dated as of May 2, 2023, by and between Reneo Pharmaceuticals, Inc. and Abingworth Bioventures 8 LP

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 2, 2023, is made by and among RENEO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Reneo Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commission

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock

EX-99.1 Exhibit 99.1 Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock IRVINE, Calif., May 3, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has commenced an underwrit

Reneo Announces Pricing of Public Offering of Common Stock

EX-99.2 Exhibit 99.2 Reneo Announces Pricing of Public Offering of Common Stock IRVINE, Calif., May 3, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the pricing of its previously announced underwri

6,875,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264616 PROSPECTUS SUPPLEMENT (To prospectus dated May 9, 2022) 6,875,000 Shares Common Stock We are offering 6,875,000 shares of our common stock. Our common stock is traded on the Nasdaq Global Market under the symbol “RPHM.” On May 2, 2023, the last reported sale price for our common stock on the Nasdaq Global Market was $9.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commission

Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264616 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

Disclaimer This presentation contains preliminary financial information as of and for the three months ended March 31, 2023 and is subject to completion. The unaudited, estimated results as of and for the three months ended March 31, 2023 are prelimi

EX-99.1 Exhibit 99.1 Focused on Improving the Lives of Patients with Rare Genetic Mitochondrial Diseases Nasdaq: RPHM Corporate Presentation May 2023 Forward-Looking Statements This presentation contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40

Subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Organization Reneo Pharma Ltd England and Wales

3 RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update IRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial

As filed with the Securities and Exchange Commission on March 27, 2023

As filed with the Securities and Exchange Commission on March 27, 2023 Registration No.

Reneo Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (incorporated by reference to Exhibit 10.9 to Reneo’s Annual Report on Form 10-K, filed on March 27, 2023).

Exhibit 10.9 Reneo Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended and restated Effective: December 06, 2022 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Reneo Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commiss

Forms of (i) Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise, (ii) Stock Option Grant Notice—International, Stock Option Agreement—International and Notice of Exercise—International and (iii) Non-Employee Director Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise—Non-Employee Director under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.18 to Reneo’s Annual Report on Form 10-K, filed on March 27, 2023).

Exhibit 10.18 RENEO PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Reneo Pharmaceuticals, Inc. (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Reneo Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Reneo Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Reneo Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commis

Investment Highlights Financial Overview Mitochondrial Diseases R&D Milestones Mavodelpar (REN001) Preliminary evidence of efficacy and tolerability from four clinical trials Favorable guidance from U.S. and European regulatory agencies Rare diseases

EX-99.1 2 d418382dex991.htm EX-99.1 Exhibit 99.1 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo

Reneo Pharmaceuticals, Inc. Severance Benefit Plan, as amended as of September 27, 2022, and form of Participation Agreement thereunder (incorporated by reference to Exhibit 10.2 to Reneo’s Quarterly Report on Form 10-Q, filed on November 8, 2022).

Exhibit 10.2 Reneo Pharmaceuticals, Inc. Severance Benefit Plan Approved by the Board of Directors: January 31, 2018 Amended as of September 7, 2021 Amended as of September 27, 2022 Section 1. Introduction. The Reneo Pharmaceuticals, Inc. Severance Benefit Plan (the ?Plan?) is hereby established effective as of January 31, 2018 (the ?Effective Date?), and most recently amended as of September 27,

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results IRVINE, Calif., November 8, 2022 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September 30

RPHM / Reneo Pharmaceuticals, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E 103 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. S

POWER OF ATTORNEY

Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings.

RPHM / Reneo Pharmaceuticals, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E103 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-562

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2022 Reneo Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40315 47-2309515 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40315 Reneo Phar

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

Exhibit 99.1 Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results IRVINE, Calif., August 9, 2022 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June 30, 2022

Letter Agreement by and between Reneo and Roshawn Blunt, dated August 2, 2022 (incorporated by reference to Exhibit 10.2 to Reneo’s Quarterly Report on Form 10-Q, filed on August 9, 2022).

Exhibit 10.2 August 2, 2022 Roshawn Blunt RE: Member of the Reneo Board of Directors Dear Roshawn: This letter confirms our understanding regarding the terms of your service as a member of the Board of Directors (the ?Board?) of Reneo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), contingent and effective upon your appointment as a director by the Board. Nothing in this is meant, o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commiss

Submission of Matters to a Vote of Security Holders

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 1, 2022 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40315 47-2309515 (State or other jurisdiction of incorpo

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 10, 2022 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40315 47-2309515 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets (In thousands, except share and par value data)

? ? Exhibit 99.1 ? Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended March 31,

RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, California 92612

CORRESP 1 filename1.htm RENEO PHARMACEUTICALS, INC. 18575 Jamboree Road, Suite 275-S Irvine, California 92612 May 5, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Michael Davis Re: Reneo Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-264616) Request for Acceleration of Effective Date De

As filed with the Securities and Exchange Commission on May 2, 2022

Table of Contents As filed with the Securities and Exchange Commission on May 2, 2022 Registration No.

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.6 RENEO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF RENEO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between RENEO PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and

Form of Indenture, by and between the Registrant and one or more trustees to be named.

Exhibit 4.3 RENEO PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 7

Sales Agreement, dated May 2, 2022, by and between the Registrant and SVB Securities LLC (incorporated by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3 (File No. 333-264616), filed with the SEC on May 2, 2022).

Exhibit 1.2 RENEO PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT May 2, 2022 SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Reneo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows: 1. Issuance

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.8 RENEO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF RENEO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between RENEO PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Reneo Pharmaceuticals, Inc.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.7 RENEO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF RENEO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between RENEO PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Transition, Separation and Consulting Agreement by and between the Registrant and Wendy Johnson, dated December 23, 2021

? EXHIBIT 10.12 December 21, 2021 Wendy Johnson 3115 3rd Avenue San Diego CA 92103 Re:Transition, Separation and Consulting Agreement Dear Wendy: This letter sets forth the substance of the transition, separation and consulting agreement (the ?Agreement?) that Reneo Pharmaceuticals, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1.Separation. Your last day of work wi

Transition, Separation and Consulting Agreement by and between the Registrant and Vineet R. Jindal, dated February 2, 2022.

?Exhibit 10.14 ? February 2, 2022 Vineet R. Jindal 5521 Linmore Lane Plano, TX 75093 Re:Transition, Separation and Consulting Agreement Dear Vinny: This letter sets forth the substance of the transition, separation and consulting agreement (the ?Agreement?) that Reneo Pharmaceuticals, Inc. (the ?Company?) is offering to you to aid in your employment transition. 1.Separation. Your last day of work

As filed with the Securities and Exchange Commission on March 23, 2022

As filed with the Securities and Exchange Commission on March 23, 2022 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 23, 2022 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-40315 47-2309515 (State or other jurisdiction of incor

RENEO PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except par value and share data)

? ? Exhibit 99.1 ? Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Irvine, Calif. March 23, 2022 - Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for

Reneo Pharmaceuticals, Inc. 2021 Non-Employee Director Compensation Policy, as amended

? EXHIBIT 10.11 ? Reneo Pharmaceuticals, Inc. ? Non-Employee Director Compensation Policy ? Amended Effective: FEBRUARY 25, 2022 ? Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Reneo Pharmaceuticals, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Subsidiaries of the Registrant.

EXHIBIT 21.1 ? subsidiaries of reneo pharmaceuticals, Inc. ? ? Name of Subsidiary Jurisdiction of Incorporation ? Reneo Pharma Ltd ? United Kingdom ?

Letter Agreement by and between Reneo and Paul W. Hoelscher, dated January 20, 2022 (incorporated by reference to Exhibit 10.13 to Reneo’s Annual Report on Form 10-K, filed on March 23, 2022).

?Exhibit 10.13 ?? ? January 20, 2022 ? Paul W. Hoelscher ? RE: Member of the Reneo Board of Directors ? Dear Paul: ? This letter confirms our understanding regarding the terms of your appointment as a member of the Board of Directors (the ?Board?) of Reneo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), contingent and effective upon your execution of this letter. In addition, you wi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Reneo Pharmaceuticals, Inc.

Description of Common Stock of the Registrant (incorporated by reference to Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K (File No. 001-40315), filed with the SEC on March 23, 2022).

? Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the common stock of Reneo Pharmaceuticals, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this ?Description of Common Stock,? you should refer to our amended and restat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commissi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 Reneo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40315 47-2309515 (State or other jurisdiction of incorporation) (Commi

RPHM / Reneo Pharmaceuticals, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Reneo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 75974E 103 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy